Drug Patents owned by Radiomedix
1. List of Detectnet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10159759 | RADIOMEDIX | Pet tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| US10383961 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| US11160888 | RADIOMEDIX | PET tracer for imaging of neuroendocrine tumors |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 3, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 3, 2027 |
Drugs and Companies using COPPER DOTATATE CU-64 ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 03 September, 2020
Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic